Treatment for peritoneal carcinomatosis often requires a combination of therapies. The exact plan depends on where the cancer started, how far it has spread and your overall health. Your healthcare team also considers your treatment goals, such as extending life, symptom relief or both.
Systemic chemotherapy
The most common treatment for peritoneal carcinomatosis is systemic chemotherapy. This is medicine given through the blood to reach the whole body. Chemotherapy uses strong medicines to kill cancer cells, help shrink tumors, and relieve symptoms such as pain or bloating. Chemotherapy also may allow for surgery later.
However, systemic chemotherapy doesn't reach the peritoneum as well as it does other parts of the body, which can limit how well it works for peritoneal carcinomatosis.
Immunotherapy
Immunotherapy is another type of systemic treatment that may be offered for certain cancers.
Cytoreductive surgery
Cytoreductive surgery (CRS) removes all visible cancer from the peritoneum and other organs in the abdomen. Also known as debulking surgery, CRS is a major operation and should only be done in centers with experience. It's best for people who are healthy enough for surgery and whose cancer can be mostly or completely removed.
Hyperthermic intraperitoneal chemotherapy
Hyperthermic intraperitoneal chemotherapy (HIPEC) is typically combined with CRS. After the cancer is removed during surgery, the abdominal cavity is bathed with heated chemotherapy to target any remaining microscopic cancer cells.
This combined approach, often referred to as CRS-HIPEC or HIPEC surgery, allows for higher medicine concentrations to reach cancer in the peritoneum. This can lessen the typical side effects people often have with systemic chemotherapy due to less absorption in the bloodstream.
Research has shown that HIPEC can prevent cancer from returning for certain people whose cancer has spread to the abdominal cavity. Therefore, HIPEC may prolong survival.
Pressurized intraperitoneal aerosolized chemotherapy
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a newer method to treat peritoneal carcinomatosis. During PIPAC, a special aerosolized mist of chemotherapy medicine is put directly into the belly during a minimally invasive procedure. The medicine is given as a fine aerosol under pressure, which helps it spread evenly throughout the abdomen. PIPAC is typically done when surgery isn't possible or when surgery would be too risky or not helpful.
Palliative care
When peritoneal carcinomatosis can't be cured or treated with chemotherapy or surgery, the focus may turn to comfort and quality of life. Palliative care is a special type of healthcare that focuses on relieving pain and other symptoms, such as digestive issues, malnutrition and fluid buildup, called ascites. Treatments may include fluid drainage, pain relief medicines and nutritional support.
Palliative care involves a team of healthcare professionals. The team can include doctors, nurses and other specially trained health professionals. The goal is to improve the quality of life for people with serious illnesses and their families.
Prognosis
Peritoneal carcinomatosis is a serious and often late-stage condition. Depending on how aggressive the cancer is, people with peritoneal carcinomatosis from more advanced cancers may live only 4 to 6 months on average when treated with systemic chemotherapy alone.
However, some people may live longer if they are healthy enough to have CRS-HIPEC. In some studies, CRS-HIPEC extended survival by more than three years. For people who can't have surgery, newer treatments such as PIPAC also may help them live longer.